Advertisement

Topics

Biosimilar insulin lispro shown not inferior to Humalog® in efficacy or safety

20:00 EDT 8 Aug 2017 | AAAS

(Mary Ann Liebert, Inc./Genetic Engineering News) A study comparing the safety and efficacy of SAR342434, a biosimilar (follow-on form) of insulin lispro-Humalog®, found it to be comparable to that of the brand name drug in patients also using insulin glargine.

Original Article: Biosimilar insulin lispro shown not inferior to Humalog® in efficacy or safety

NEXT ARTICLE

More From BioPortfolio on "Biosimilar insulin lispro shown not inferior to Humalog® in efficacy or safety"

Quick Search
Advertisement
 

Relevant Topics

Genetic Engineering
Genetic engineering is the process of manually adding new DNA to an organism. The goal is to add one or more new traits that are not already found in that organism. Examples of genetically engineered (transgenic) organisms currently on the market include...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...